STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Dare Bioscience, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary

Law Custodial Inc. filed a Schedule 13G reporting beneficial ownership of 1,409,167 ordinary shares of Dare Bioscience, Inc., representing approximately 15.9% of the 8,871,155 shares outstanding used for the calculation. The filing states the shares were not acquired to change or influence control and that 795,271 of the shares are held as trustee with sole voting and dispositive power. The reporting person is organized in Samoa with a principal address in Hong Kong and the signature is dated 10/06/2025. This ownership level exceeds 5% and must be disclosed under the Exchange Act.

Positive
  • Clear disclosure of aggregate ownership: 1,409,167 shares representing 15.9%
  • Certification that holdings are passive and not intended to change control
Negative
  • Large passive stake of 15.9% could concentrate voting power and influence
  • Partial trustee holdings: 795,271 shares held as trustee with sole voting power increases practical control

Insights

Law Custodial reports a material 15.9% stake with sole voting control over 1.41M shares.

The filing discloses total beneficial ownership of 1,409,167 ordinary shares, using a share base of 8,871,155 to compute 15.9%. The statement that 795,271 shares are held as trustee with sole voting and dispositive power indicates direct control over a substantial subset of the position.

This holding level is material to investors because it passes the 5% disclosure threshold; monitor any future amendments or Schedule 13D filings that would signal an active intent to influence corporate control within typical SEC reporting horizons.

The filer certifies the position is not held to influence control and cites nomination-only activities.

The certification language states the shares "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" and excludes other coordinated group activity. That classification governs reporting obligations and signals passive intent under the rules cited.

Governance risks to watch include any later reclassification to an active investor filing (Schedule 13D) or public disclosures of coordination, which would materially change the company's shareholder landscape within a near-term period if they occur.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



LAW CUSTODIAL INC.
Signature:Shane Frederick Weir
Name/Title:Director
Date:10/06/2025

FAQ

What stake in Dare Bioscience (DARE) does Law Custodial Inc. report?

Law Custodial Inc. reports beneficial ownership of 1,409,167 ordinary shares, or approximately 15.9% of the class.

How many shares were used to calculate the 15.9% figure?

The percentage is calculated using 8,871,155 shares outstanding as of 30 June 2025.

Does Law Custodial claim the shares are intended to change control of DARE?

No. The filing includes a certification stating the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control."

How many of the reported shares are held as trustee with sole voting power?

795,271 of the shares are held as trustee with sole voting and dispositive power according to the filing.

Where is Law Custodial Inc. organized and where is its principal office listed?

The reporting person is organized in Samoa with a principal business address in Hong Kong at 6/F, Wings Building, 110-116 Queen's Road Central.
Dare Bioscience Inc

NASDAQ:DARE

DARE Rankings

DARE Latest News

DARE Latest SEC Filings

DARE Stock Data

23.29M
12.74M
1.03%
6.71%
1.46%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO